ClinicalTrials.gg

Program

solriamfetol

Also written as “JZP-110”, “Solriamfetol” and “Solriamfetol 300 mg”.

Its studies are mostly in Narcolepsy · Attention Deficit Disorder with Hyperactivity · Sleep Apnea, Obstructive · Depressive Disorder, Major · Disorders of Excessive Somnolence, led by 4 companies.

Furthest: phase 4, since Feb 25, 202122 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Axsome Therapeutics117 open or runningphase 4since Feb 25, 2021Feb 25, 2021Dec 2026phase 3 · NCT06413433
Jazz Pharmaceuticals90 open or runningphase 3since Jan 15, 2015Dec 2, 2011none ahead
Ignis Therapeutics (Suzhou)10 open or runningphase 3since Sep 27, 2023Sep 27, 2023none ahead
Johnson & Johnson10 open or runningphase 2since Nov 17, 2003Nov 17, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 17, 2003.

  1. Jan 15, 20154 phase 3 studiesJazz Pharmaceuticals · NCT02348632, NCT02348619, NCT02348606 and 1 more
  2. Jun 10, 20162 phase 2 studiesJazz Pharmaceuticals · NCT02806908, NCT02806895
  3. Jan 23, 2017Phase 2 study in Disorders of Excessive SomnolenceJazz Pharmaceuticals · NCT03037203 · 66 enrolled · United States
  4. Feb 25, 2021Axsome Therapeutics's first study: phase 4 study in Disorders of Excessive SomnolenceNew to Axsome TherapeuticsAxsome Therapeutics · NCT04789174 · 59 enrolled · United States, Canada, Italy and more
  5. Aug 10, 2021Phase 1 study in NarcolepsyAxsome Therapeutics · NCT05008341 · 6 enrolled · United States
  6. Jul 25, 2023Phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT05972044 · 516 enrolled · United States
  7. Sep 27, 2023Ignis Therapeutics (Suzhou)'s first study: phase 3 study in Sleep Apnea, ObstructiveNew to Ignis Therapeutics (Suzhou)Ignis Therapeutics (Suzhou) · NCT06103825 · 204 enrolled · China
  8. Apr 8, 2024Phase 3 study in Depressive Disorder, MajorAxsome Therapeutics · NCT06360419 · 346 enrolled · United States
  9. May 9, 2024Phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06413433 · 450 planned · United States
  10. Aug 21, 2024Phase 3 study in Disorders of Excessive SomnolenceAxsome Therapeutics · NCT06568367 · 520 planned · United States, Canada
  11. Mar 14, 2025Phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06878976 · 236 planned · United States
  12. Mar 16, 2026Phase 3 study in Depressive Disorder, MajorAxsome Therapeutics · NCT07484217 · 508 planned · United States
  13. Jul 16, 20262 phase 3 studies in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07717892, NCT07717879
  14. Aug 14, 2026Phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07773883 · 300 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Disorders of Excessive SomnolenceAxsome Therapeutics · NCT06568367
  2. Dec 2026Primary completion: phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06413433
  3. Dec 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07773883
  4. Dec 2027Primary completion: phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06878976

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07773883Attention Deficit Disorder with Hyperactivity · United States3By invitationAxsome TherapeuticsDec 2027300
NCT07717892Attention Deficit Disorder with Hyperactivity · United States3RecruitingAxsome TherapeuticsJun 30, 2028468
NCT07717879Attention Deficit Disorder with Hyperactivity · United States3RecruitingAxsome TherapeuticsJun 30, 2028468
NCT07484217Depressive Disorder, Major · United States3RecruitingAxsome TherapeuticsDec 2028508
NCT06878976Binge-Eating Disorder · United States3By invitationAxsome TherapeuticsDec 2027236
NCT06568367Disorders of Excessive Somnolence · United States, Canada3RecruitingAxsome TherapeuticsDec 2026520
NCT06413433Binge-Eating Disorder · United States3RecruitingAxsome TherapeuticsDec 2026450
NCT06360419Depressive Disorder, Major · United States3CompletedAxsome TherapeuticsDec 31, 2024346
NCT06103825Sleep Apnea, Obstructive · China3CompletedIgnis Therapeutics (Suzhou)Jul 20, 2024204
NCT05972044Attention Deficit Disorder with Hyperactivity · United States3CompletedAxsome TherapeuticsFeb 7, 2025516
NCT05008341Narcolepsy · United States1CompletedAxsome TherapeuticsApr 15, 20226
NCT04789174Disorders of Excessive Somnolence · United States, Canada, Italy and more4CompletedAxsome TherapeuticsSep 19, 202259
NCT03037203Disorders of Excessive Somnolence · United States2CompletedJazz PharmaceuticalsAug 201866
NCT02806908Narcolepsy · Netherlands2CompletedJazz PharmaceuticalsMay 19, 201924
NCT02806895Sleep Apnea, Obstructive · Netherlands2CompletedJazz PharmaceuticalsMay 28, 201934
NCT02348632Narcolepsy · United States, Canada, Finland and more3CompletedJazz PharmaceuticalsDec 2017645
NCT02348619Sleep Apnea, Obstructive · United States, Finland, France and more3CompletedJazz PharmaceuticalsNov 2016174
NCT02348606Sleep Apnea, Obstructive · United States, Canada, France and more3CompletedJazz PharmaceuticalsDec 2016476
NCT02348593Narcolepsy · United States, Canada, Finland and more3CompletedJazz PharmaceuticalsFeb 2017239
NCT01681121Narcolepsy · United States2CompletedJazz PharmaceuticalsAug 201393
NCT01485770Narcolepsy · United States2CompletedJazz PharmaceuticalsMay 201233
NCT00073203Depressive Disorder, Major · United States2CompletedJohnson & Johnson488

How it is read

Names in the registry

  • “JZP-110”, 7 entries
  • “Solriamfetol”, 4 entries
  • “Solriamfetol 300 mg”, 4 entries
  • “Solriamfetol 150 mg”, 3 entries
  • “Solriamfetol Dose A”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.